IRF5 and systemic lupus erythematosus: Given that dysregulated functions of TLRs have also been implicated in SLE, and IRF5 is a critical downstream mediator of MyD88-dependent TLR signaling, the identification of kinases that regulate the TLR-mediated activation of IRF5 may lead to the development of therapeutic agents for the treatment of patients with autoimmune and inflammatory conditions.